
Insights on NervGen Pharma’s Positive Phase 1b/2a Data for NVG-291 in Spinal Cord Injury
Earlier this month, NervGen Pharma, a clinical-stage biotech company, announced topline data from its phase 1b/2a trial (NCT05965700) assessing its lead drug candidate, NVG-291, as a potential treatment for spinal cord injury (SCI). The study featured …